Literature DB >> 20017668

Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.

Tejinder K Rakhra-Burris1, J Todd Auman, Patricia Deverka, Lynn G Dressler, James P Evans, Richard M Goldberg, Tammy M Havener, Janelle M Hoskins, Daniel E Jonas, Kevin M Long, Alison A Motsinger-Reif, William J Irvin, Kristy L Richards, Mary W Roederer, John M Valgus, Marcia van Riper, John A Vernon, William C Zamboni, Michael J Wagner, Christine M Walko, Karen E Weck, Tim Wiltshire, Howard L McLeod.   

Abstract

The Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina at Chapel Hill (NC, USA) is a collaborative, multidisciplinary unit that brings together faculty from different disciplines and crosses the traditional departmental/school structure to perform pharmacogenomics research. IPIT investigators work together towards the goal of developing therapies to enable the delivery of individualized medical care. The NIH-supported Comprehensive Research on Expressed Alleles in Therapeutic Evaluation (CREATE) group leads the field in the evaluation of pathways regulating drug activity, and also provides a foundation for future IPIT research. IPIT members perform bench research, clinical cohort analysis and prospective clinical intervention studies, research on the integration of pharmacogenomic therapy into practice and research to foster global health pharmacogenomics application through the Pharmacogenetics for Every Nation Initiative. IPIT Investigators are actively incorporating a pharmacogenomics curriculum into existing teaching programs at all levels.

Mesh:

Substances:

Year:  2010        PMID: 20017668     DOI: 10.2217/pgs.09.167

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  1 in total

1.  Current practices in the delivery of pharmacogenomics: Impact of the recommendations of the Pharmacy Practice Model Summit.

Authors:  John Valgus; Kristin W Weitzel; Josh F Peterson; Daniel J Crona; Christine M Formea
Journal:  Am J Health Syst Pharm       Date:  2019-04-08       Impact factor: 2.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.